Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press39910.17650/1726-9776-2014-10-4-70-74PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫLuteinizing hormone-releasing hormone antagonists in patients with prostate cancer. A standard approach and the results of innovative studiesАнтагонисты лютеинизирующего гормона рилизинг-гормона у больных раком предст ательной железы. Ст андартный подход и резу льтаты инновационных исследованийNyushkoK. M.НюшкоК. М.
Russian Federation
kirandja@yandex.ruAlekseevB. Ya.АлексеевБ. Я.
Russian Federation
KalpinskyA. S.КалпинскийА. С.
Russian Federation
KaprinA. D.КапринА. Д.
Russian Federation
P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of RussiaФГБУ «Московский научно-исследовательский онкологический институт им. П.А. Герцена» Минздрава России3, Second Botkinsky Pr., Moscow 125284125284 Москва, 2-й Боткинский пр., 33, Second Botkinsky Pr., Moscow 125284 Department of Urology with Course of Urologic Oncology, Faculty for Postgraduate Training of Health Workers, Peoples’ Friendship University of Russia125284 Москва, 2-й Боткинский пр., 3 кафедра урологии с курсом онкоурологии ФПК МР РУДН21, Miklukho-Maklai St., Moscow 117198Россия, 117198 Москва, ул. Миклухо-Маклая, 21 кафедра онкологии МИУВ ГБОУ ВПО «Московский государственный университет пищевых производств»Россия, 125080 Москва, Волоколамское шоссе, 11P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia3, Second Botkinsky Pr., Moscow 125284 Department of Urology with Course of Urologic Oncology, Faculty for Postgraduate Training of Health Workers, Peoples’ Friendship University of RussiaФГБУ «Московский научно-исследовательский онкологический институт им. П.А. Герцена» Минздрава России21, Miklukho-Maklai St., Moscow 117198 Department of Oncology, Medical Institute for Postgraduate Training of Physicians, Moscow State University of Food Productions125284 Москва, 2-й Боткинский пр., 3 кафедра урологии с курсом онкоурологии ФПК МР РУДН11, Volokolamskoye Shosse, Moscow 125080, RussiaРоссия, 117198 Москва, ул. Миклухо-Маклая, 2121, Miklukho-Maklai St., Moscow 117198Россия, 117198 Москва, ул. Миклухо-Маклая, 213012201410470740112201401122014https://oncourology.abvpress.ru/oncur/article/view/399

Prostate cancer (PC) is one of the most burning problems of modern urologic oncology. Hormonal therapy (HT) using medical castrationremains a basic therapy for metastatic PC. HT with a novel class of luteinizing hormone-releasing hormone (LHRH) receptor antagonists isa promising and effective castration treatment option that has a number of significant advantages over LHRH analogues. The paper reviews the results of trials comparing the efficiency and adverse reactions of HT using LHRH antagonists and analogues and gives those of a Russian multicenter study covering the countrywide experience with degarelix.

Рак предстательной железы (РПЖ) является одной из наиболее актуальных проблем современной онкоурологии. Гормональная терапия (ГТ) с использованием медикаментозной кастрации остается основным методом лечения больных метастатическим РПЖ. ГТ с использованием нового класса препаратов, блокирующих рецепторы лютеинизирующего гормона рилизинг-гормона (ЛГРГ), – перспективный и эффективный метод кастрационной терапии, обладающий рядом существенных преимуществ перед аналогами ЛГРГ. В статье представлен обзор результатов исследований по сравнению эффективности и побочных эффектов ГТ с использованием антагонистов и аналогов ЛГРГ, приведены результаты российского многоцентрового исследования, осветившего отечественный опыт применения дегареликса.

prostate cancerluteinizing hormone-releasing hormone analogues and antagonistsdegarelixcastration-refractorinesscardiovascular diseasecardiovascular riskрак предстательной железыаналоги и антагонисты лютеинизирующего гормона рилизинг-гормонадегареликскастрационная рефрактерностьсердечно-сосудистая патологиякардиоваскулярный риск1. Состояние онкологической помощи населению России в 2012 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2013.Состояние онкологической помощи населению России в 2012 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2013.2. Huggins C., Hoges C.V. Studies on prostate cancer. The effect of castration. Cancer Res 1941:385–402.Huggins C., Hoges C.V. Studies on prostate cancer. The effect of castration. Cancer Res 1941:385–402.3. Malkowicz S.B. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001;58(2 Suppl 1):108–13.Malkowicz S.B. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001;58(2 Suppl 1):108–13.4. Kaisary A.V., Tyrrell C.J., Peeling W.B. et al. Comparison of LHRH analogue with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67(5):502–8.Kaisary A.V., Tyrrell C.J., Peeling W.B. et al. Comparison of LHRH analogue with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67(5):502–8.5. Keating N.L., O'Malley A.J., Freedland S.J. et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. JNCI J Natl Cancer Inst 2010;102:39–46.Keating N.L., O'Malley A.J., Freedland S.J. et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. JNCI J Natl Cancer Inst 2010;102:39–46.6. Bubley G.J. Is the flare phenomenon clinically significant? Urology 2001;58 (2 Suppl 1):5–9.Bubley G.J. Is the flare phenomenon clinically significant? Urology 2001;58 (2 Suppl 1):5–9.7. Bertaglia V., Tucci M., Fiori C. et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer 2013;11(3):325–30.Bertaglia V., Tucci M., Fiori C. et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer 2013;11(3):325–30.8. Rick F.G., Block N.L., Schally A.V. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther 2013;6:391–402.Rick F.G., Block N.L., Schally A.V. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther 2013;6:391–402.9. Anderson J. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer. Future Oncol 2009;5(4):433–43.Anderson J. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer. Future Oncol 2009;5(4):433–43.10. Persson B.E., Kold Olesen T., Jensen J.K. Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology 2009;90(3):235–44.Persson B.E., Kold Olesen T., Jensen J.K. Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology 2009;90(3):235–44.11. Klotz L., Boccon-Gibod L., Shore N.D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, openlabel, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11):1531–8.Klotz L., Boccon-Gibod L., Shore N.D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, openlabel, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11):1531–8.12. Crawford E.D., Shore N.D., Moul J.W. et al. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology 2014;83(5):1122–8.Crawford E.D., Shore N.D., Moul J.W. et al. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology 2014;83(5):1122–8.13. Klotz L., Miller K., Crawford E.D. et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormonereleasing hormone agonists. Eur Urol 2014 Jan 9. pii: S0302–2838(13)01491–7.Klotz L., Miller K., Crawford E.D. et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormonereleasing hormone agonists. Eur Urol 2014 Jan 9. pii: S0302–2838(13)01491–7.14. Miller K., Rüssel C., Goble S. et al. Open-label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate cancer (CS27). EAU 2013; Poster 678.Miller K., Rüssel C., Goble S. et al. Open-label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate cancer (CS27). EAU 2013; Poster 678.15. Van Poppel H., Klotz L. Gonadotropinreleasing hormone: an update review of the antagonists versus agonists. Int J Urol 2012;19(7):594–601.Van Poppel H., Klotz L. Gonadotropinreleasing hormone: an update review of the antagonists versus agonists. Int J Urol 2012;19(7):594–601.16. Smith M.R., Klotz L., van der Meulen E. et al. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol 2011;186(5): 1835–42.Smith M.R., Klotz L., van der Meulen E. et al. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol 2011;186(5): 1835–42.17. Tanriverdi F., Gonzalez-Martinez D., Hu Y. et al. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol 2005;142(1):103–10.Tanriverdi F., Gonzalez-Martinez D., Hu Y. et al. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol 2005;142(1):103–10.18. Chen H.F., Jeung E.B., Stephenson M., Leung P.C. Human peripheral blood mononuclear cells express gonadotropinreleasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab 1999;84(2):743–50.Chen H.F., Jeung E.B., Stephenson M., Leung P.C. Human peripheral blood mononuclear cells express gonadotropinreleasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab 1999;84(2):743–50.